Dr. Elizabeth Plimack reviews how KEYNOTE-B61 supports lenvatinib plus pembrolizumab as a strong frontline option in non–clear cell RCC, particularly in papillary disease. She also discusses LITESPARK-011, noting that while lenvatinib plus belzutifan shows benefit, sequencing decisions remain complex, especially for patients already treated with lenvatinib-based regimens. In practice, she emphasizes balancing efficacy, durability, and tolerability, often reserving belzutifan for later lines while optimizing TKI dosing to maintain long-term benefit.
Belzutifan Moves Earlier in Kidney Cancer Care
Dr. Laurence Albiges outlines how belzutifan is reshaping kidney cancer treatment across disease stages. In the adjuvant setting, adding belzutifan
